Viking Therapeutics's total assets for Q4 2024 were $908.32M, a decrease of -3.15% from the previous quarter. VKTX total liabilities were $28.04M for the fiscal quarter, a 6.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.